Flow cytometry-based assay to evaluate human serum MUC1-Tn antibodies

Journal of Immunological Methods

Volumn 365, Issue 1-2, 2011, Pages 87-94

  Van Elssen, Catharina H M J ^a,b   Clausen, Henrik ^c   Germeraad, Wilfred T V ^a   Bennet, Eric P ^c   Menheere, Paul P ^a   Bos, Gerard M J ^a   Vanderlocht, Joris ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PharmaCell BV   (Netherlands)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Breast cancer; CHO ldlD; Flow cytometry; Gal; GalNAc; Glycosylation; MUC1; Serum antibodies; Tn

Indexed keywords

KEYHOLE LIMPET HEMOCYANIN; MONOSACCHARIDE; MUCIN 1; TN ANTIGEN;

ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; BREAST CANCER; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; GLYCOSYLATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CASE-CONTROL STUDIES; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; FLOW CYTOMETRY; GLYCOSYLATION; HUMANS; MOLECULAR SEQUENCE DATA; MUCIN-1; RECOMBINANT PROTEINS; TRANSFECTION; VACCINES, SUBUNIT;

CRICETULUS GRISEUS;

EID: 79551583090     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.12.006     Document Type: Article

References (40)

1. Altschuler Y., Kinlough C.L., Poland P.A., Bruns J.B., Apodaca G., Weisz O.A., Hughey R.P. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol. Biol. Cell 2000, 11:819.
2. Apostolopoulos V., Pietersz G.A., Tsibanis A., Tsikkinis A., Drakaki H., Loveland B.E., Piddlesden S.J., Plebanski M., Pouniotis D.S., Alexis M.N., McKenzie I.F., Vassilaros S. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006, 8:R27.
3. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 2006, 7:599.
4. Chandrasekaran E.V., Xue J., Neelamegham S., Matta K.L. The pattern of glycosyl- and sulfotransferase activities in cancer cell lines: a predictor of individual cancer-associated distinct carbohydrate structures for the structural identification of signature glycans. Carbohydr. Res. 2006, 341:983.
5. Cloosen S., Arnold J., Thio M., Bos G.M., Kyewski B., Germeraad W.T. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res. 2007, 67:3919.
6. Colomer R., Ruibal A., Genolla J., Salvador L. Circulating CA 15-3 antigen levels in non-mammary malignancies. Br. J. Cancer 1989, 59:283.
7. Croce M.V., Isla-Larrain M.T., Demichelis S.O., Gori J.R., Price M.R., Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res. Treat. 2003, 81:195.
8. Gendler S.J. MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia 2001, 6:339.
9. Hamanaka Y., Suehiro Y., Fukui M., Shikichi K., Imai K., Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer 2003, 103:97.
10. Julien S., Picco G., Sewell R., Vercoutter-Edouart A.S., Tarp M., Miles D., Clausen H., Taylor-Papadimitriou J., Burchell J.M. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br. J. Cancer 2009, 100:1746.
11. Kas-Deelen A.M., Harmsen M.C., de Maar E.F., van Son W.J., The T.H. A sensitive method for quantifying cytomegalic endothelial cells in peripheral blood from cytomegalovirus-infected patients. Clin. Diagn. Lab. Immunol. 1998, 5:622.
12. Kingsley D.M., Kozarsky K.F., Hobbie L., Krieger M. Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNAc 4-epimerase deficient mutant. Cell 1986, 44:749.
13. Kotera Y., Fontenot J.D., Pecher G., Metzgar R.S., Finn O.J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 1994, 54:2856.
14. Krieger M., Brown M.S., Goldstein J.L. Isolation of Chinese hamster cell mutants defective in the receptor-mediated endocytosis of low density lipoprotein. J. Mol. Biol. 1981, 150:167.
15. Lepisto A.J., Moser A.J., Zeh H., Lee K., Bartlett D., McKolanis J.R., Geller B.A., Schmotzer A., Potter D.P., Whiteside T., Finn O.J., Ramanathan R.K. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008, 6:955.
16. Moreno M., Bontkes H.J., Scheper R.J., Kenemans P., Verheijen R.H., von Mensdorff-Pouilly S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett. 2007, 257:47.
17. Nakamura H., Hinoda Y., Nakagawa N., Makiguchi Y., Itoh F., Endo T., Imai K. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J. Gastroenterol. 1998, 33:354.
18. Pinho S., Marcos N.T., Ferreira B., Carvalho A.S., Oliveira M.J., Santos-Silva F., Harduin-Lepers A., Reis C.A. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 2007, 249:157.
19. Pochampalli M.R., el Bejjani R.M., Schroeder J.A. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007, 26:1693.
20. Richards E.R., Devine P.L., Quin R.J., Fontenot J.D., Ward B.G., McGuckin M.A. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol. Immunother. 1998, 46:245.
21. Rosenberg S.A., Sherry R.M., Morton K.E., Scharfman W.J., Yang J.C., Topalian S.L., Royal R.E., Kammula U., Restifo N.P., Hughes M.S., Schwartzentruber D., Berman D.M., Schwarz S.L., Ngo L.T., Mavroukakis S.A., White D.E., Steinberg S.M. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 2005, 175:6169.
22. Sabbatini P.J., Ragupathi G., Hood C., Aghajanian C.A., Juretzka M., Iasonos A., Hensley M.L., Spassova M.K., Ouerfelli O., Spriggs D.R., Tew W.P., Konner J., Clausen H., Abu Rustum N., Dansihefsky S.J., Livingston P.O. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res. 2007, 13:4170.
23. Sorensen A.L., Reis C.A., Tarp M.A., Mandel U., Ramachandran K., Sankaranarayanan V., Schwientek T., Graham R., Taylor-Papadimitriou J., Hollingsworth M.A., Burchell J., Clausen H. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006, 16:96.
24. Tarp M.A., Sorensen A.L., Mandel U., Paulsen H., Burchell J., Taylor-Papadimitriou J., Clausen H. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007, 17:197.
25. Taylor-Papadimitriou J., Burchell J., Miles D.W., Dalziel M. MUC1 and cancer. Biochim. Biophys. Acta 1999, 1455:301.
26. Taylor-Papadimitriou J., Burchell J.M., Plunkett T., Graham R., Correa I., Miles D., Smith M. MUC1 and the immunobiology of cancer. J. Mammary Gland Biol. Neoplasia 2002, 7:209.
27. Thurnher M., Clausen H., Sharon N., Berger E.G. Use of O-glycosylation-defective human lymphoid cell lines and flow cytometry to delineate the specificity of Moluccella laevis lectin and monoclonal antibody 5F4 for the Tn antigen (GalNAc alpha 1-O-Ser/Thr). Immunol. Lett. 1993, 36:239.
28. Treon S.P., Maimonis P., Bua D., Young G., Raje N., Mollick J., Chauhan D., Tai Y.T., Hideshima T., Shima Y., Hilgers J., von Mensdorff-Pouilly S., Belch A.R., Pilarski L.M., Anderson K.C. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 2000, 96:3147.
29. van de Wiel-van Kemenade E., Ligtenberg M.J., de Boer A.J., Buijs F., Vos H.L., Melief C.J., Hilkens J., Figdor C.G. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 1993, 151:767.
30. Van Elssen, C.H.M.J., Frings, P.W.H., Bot, F.J., Van de Vijver, K., Huls, M.B., Meek, B., Hupperets, P., Germeraad, W.T.V. and Bos, G.M.J., 2010. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 57, 597.
31. van Leeuwen E.B., Cloosen S., Senden-Gijsbers B.L., Agervig Tarp M., Mandel U., Clausen H., Havenga M.J., Duffour M.T., Garcia-Vallejo J.J., Germeraad W.T., Bos G.M. Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector. Cytotherapy 2006, 8:24.
32. von Mensdorff-Pouilly S., Petrakou E., Kenemans P., van Uffelen K., Verstraeten A.A., Snijdewint F.G., van Kamp G.J., Schol D.J., Reis C.A., Price M.R., Livingston P.O., Hilgers J. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int. J. Cancer 2000, 86:702.
33. von Mensdorff-Pouilly S., Vennegoor C., Hilgers J. Detection of humoral immune responses to mucins. Meth. Mol. Biol. 2000, 125:495.
34. Wandall H.H., Irazoqui F., Tarp M.A., Bennett E.P., Mandel U., Takeuchi H., Kato K., Irimura T., Suryanarayanan G., Hollingsworth M.A., Clausen H. The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation. Glycobiology 2007, 17:374.
35. Wandall H.H., Blixt O., Tarp M.A., Pedersen J.W., Bennett E.P., Mandel U., Ragupathi G., Livingston P.O., Hollingsworth M.A., Taylor-Papadimitriou J., Burchell J., Clausen H. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010, 70:1306.
36. Wei X., Xu H., Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005, 7:167.
37. Wesseling J., van der Valk S.W., Vos H.L., Sonnenberg A., Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 1995, 129:255.
38. Westerlind U., Schroder H., Hobel A., Gaidzik N., Kaiser A., Niemeyer C.M., Schmitt E., Waldmann H., Kunz H. Tumor-associated MUC1 tandem-repeat glycopeptide microarrays to evaluate serum- and monoclonal-antibody specificity. Angew. Chem. Int. Ed Engl. 2009, 48:8263.
39. Wierecky J., Mueller M., Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol. Immunother. 2006, 55:63.
40. Zhao Q., Guo X., Nash G.B., Stone P.C., Hilkens J., Rhodes J.M., Yu L.G. Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res. 2009, 69:6799.